Understanding why PMDD happens and how it can be treated is rapidly evolving, and this review pulls together the latest science in a way that matters for anyone living with the condition.
One of the most important takeaways is that PMDD is not caused by having abnormal hormone levels. Women with PMDD typically have the same levels of progesterone and its brain-active byproduct, allopregnanolone, as women without PMDD. Instead, the brain's response to these normal hormonal shifts appears to be different — specifically, the GABA system (the brain's main calming system) reacts in unusual and sometimes opposite ways to these hormones. Researchers have also found specific genetic differences in women with PMDD that affect how their cells respond to estrogen and how their GABA receptors are built, helping to explain why some people are more vulnerable.
On the treatment front, SSRIs remain a first-line option and work unusually fast for PMDD — sometimes within days — which is why they can be taken only during the luteal phase rather than every day. Several promising new medications are in development: ulipristal acetate (which blocks progesterone receptors in the brain), dutasteride (which stops progesterone from converting into allopregnanolone), and sepranolone (which blocks allopregnanolone's effects on the GABA system). These are still in early testing stages, but they represent a shift toward treatments designed specifically for the biology of PMDD.
The review also highlights that cognitive behavioral therapy (CBT) — including internet-based versions — can meaningfully reduce symptoms, and that regular exercise helps with both physical and emotional symptoms. Importantly, PMDD is linked to higher risks of postpartum depression, suicidal experiences, anxiety disorders, and even future hypertension, which underscores the importance of early recognition and comprehensive care.
Key findings
- Premenstrual symptoms affect about half of women of reproductive age worldwide; PMS affects 20-30% in the US, while PMDD ranges from 3-8% in the US to 17% in Brazil
- Altered sensitivity of the GABAergic central inhibitory system to allopregnanolone (a progesterone-derived neurosteroid) is identified as a key etiological feature of PMDD, rather than abnormal hormone levels themselves
- Dutasteride (5-alpha reductase inhibitor) prevented luteal phase increases in allopregnanolone and improved most PMDD symptoms including irritability, anxiety, sadness, food cravings, and bloating without affecting healthy controls
- Sepranolone (isoallopregnanolone), a GABA-A receptor modulating steroid antagonist, showed significant reduction in PMDD mood symptoms in a phase IIa trial, though the phase IIb trial showed a 30% higher placebo effect and the higher 16 mg dose appeared less effective than 10 mg
- Ulipristal acetate (UPA), a selective progesterone receptor modulator, showed improvement in emotional and behavioral symptoms of PMDD in a proof-of-concept RCT
- Emerging evidence links neuroinflammation expressed via the GABAergic system as an etiological factor for PMS/PMDD, with some chemokines (CCL2, CCL5, CCL11) predicting more severe PMS symptoms
Methods, briefly
Narrative review synthesizing recent literature on the pathophysiology, genetics, inflammation, comorbidities, and treatment of PMS/PMDD. No systematic search protocol or sample size is reported; the review cites 161 references spanning basic science, clinical trials, meta-analyses, and epidemiological studies.
Limitations to keep in mind
- Narrative review without systematic methodology, introducing potential selection bias in cited literature
- Many novel therapies discussed (dutasteride, sepranolone, UPA) are based on small proof-of-concept or early-phase trials and lack large confirmatory studies
- Evidence on inflammation and neuroinflammation in PMS/PMDD is described as controversial with conflicting results across studies
- Most inflammation data come from animal models with limited human research
- The review does not distinguish clearly between evidence strength for different therapeutic approaches
The latest PMDD research, in your pocket
The app’s research feed is updated daily with newly published, peer-reviewed PMDD work - summarized in plain language.